Viw Magazine

The Times


.

Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes

  • UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk
  • In a phase 2 trial in Chinese people with type 2 diabetes, UBT251 showed a mean HbA1c reduction of up to 2.16%, and a mean body weight reduction of up to 9.8% after 24 weeks, showing improvements relative to placebo and semaglutide 1 mg
  • The safety and tolerability profile of UBT251 appeared consistent with what has been observed in other clinical trials with triple-G agonists.

Read more …

LifeStyle

New Brisbane Dads Embracing Weekly Baby Classes for Fun and Bonding

If you think baby classes are only for mums and their little ones, think again! New dads across Au...

Signs Your Relationship Needs More Than Just a Date Night

Date nights get a lot of credit. Book a babysitter, go somewhere nice, put the phones away and recon...

Ever Wondered Why Cosmetic Clinics Are So Careful About What They Say Online?

No prices, no product names, no glowing influencer reviews. If cosmetic clinic marketing has ever ...

Honouring Faith and Family: Understanding Traditional Funeral Rites in Australia

Australia's funerals are as varied as its people. On a single day in any capital city, you might fin...

hacklink esim českoHerabetTrBetvpnfree books downloadzlibrarySahabetstreameastnon gamstopBetimselçuksportsgrandpashabet girişgrandpashabet girişdinamobetbetimStreamEastsohbet hattıxspintaraftarium24CrackStreamsholiganbetseo ajansıyurtdışı turseo danışmanlığıseo uzmanıgrandpashabet girişstreameastseo hizmetijojobetgrandpashabetjojobetviagra 100 mg fiyatjojobetjojobetcasibommy gift cardstreameastdeneme bonusu veren siteler 2026casibom